Keeping an Eye Out: Emerging Trends in the Management of Metastatic Uveal Melanoma

Released On
December 22, 2021

Expires On
December 21, 2022

Media Type

Completion Time
45 minutes

Hematology-Oncology, Ophthalmology

Oncology, Uveal Melanoma

Scroll to the Bottom of this Information to Begin this Course

This continuing medical education activity is provided by:


This activity is supported by an educational grant from Immunocore.

Credit Available

  • Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

The intended audience for this activity is oncologists and other health care professionals involved in the management of patients with uveal melanoma.

Program Overview

Uveal melanoma is the most common ocular cancer, typically affecting older patients, particularly men. It is associated with a high mortality rate, especially after metastases. Individuals with fair skin and eyes are more susceptible to the disease due to a lower amount of melanin. Diagnosing uveal melanoma is challenging, as only approximately 30% of patients experience symptoms, such as secondary glaucoma and changes in iris color and pupil shape, thus misdiagnosis is common. The current standard of care for uveal melanoma includes enucleation, globe-preserving therapies, or radiotherapy, but the rates of metastases remain high. Ongoing research has yielded a greater understanding of the disease mechanisms, which has led to advances in biomarkers and therapies. However, given the novelty of these studies, as well as the disease mechanisms that differ from other skin cancers, oncology providers need timely education on these topics to remain current. In this educational activity, expert faculty review the most recent data regarding the molecular basis of uveal melanoma and the clinical data supporting the use of new and emerging therapies. They also explore the potential role of novel therapies in the current treatment algorithm for uveal melanoma.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the latest understanding regarding the molecular basis of uveal melanoma.
  • Critically appraise the latest data regarding the safety and efficacy of new/emerging treatment options for patients with advanced uveal melanoma.
  • Outline how new or emerging options may fit into existing treatment algorithms for patients with uveal melanoma.


Activity Chair


Alexander N. Shoushtari, MD

Assistant Attending Physician and Clinical Director, Melanoma Service
Memorial Sloan Kettering Cancer Center
Assistant Professor, Department of Medicine
Weill Cornell Medical College
New York, NY




Prof. Dr. med. Jessica C. Hassel

Section Head, Associate Professor
Section of DermatoOncology
Department of Dermatology and National Center for Tumor Diseases
University Hospital Heidelberg
Heidelberg, Germany



Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Physician Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Vindico Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relevant financial relationship(s):

Alexander N. Shoushtari, MD
  • Consultant: Bristol-Myers Squibb, Immunocore, Novartis
Prof. Dr. med. Jessica C. Hassel
  • Advisor:: Merck Sharp & Dohme
  • Speaker Contracted by Ineligible Company: Almirall, Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer, Roche
  • Independent Research Contractor: Bristol-Myers Squibb

Reviewer reports the following relevant financial relationship(s):

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP: No relevant financial relationships to disclose.

Vindico Medical Education Staff reports the following relevant financial relationship(s): No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit, for this enduring activity. To receive CME credit participants must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Unlabeled and Investigational Usage:

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Copyright Statement:

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information

For CME questions please contact: